Associated Papers
DNA polymerase ε and δ variants drive mutagenesis in polypurine tracts in human tumors.
Ostroverkhova D et al.
Cell Reports, 2024
38219146 (PubMed )
Supplement: NIHMS1961519-supplement-16.xlsx › Table_S7
Clinical and genetic characteristics in lymphoma patients with a second solid malignancy.
Zhou D et al.
Frontiers in Oncology, 2023
37546421 (PubMed )
Supplement: DataSheet_1.xlsx › Sheet1
Detection of oncogenic and clinically actionable mutations in cancer genomes critically depends on variant calling tools.
Garcia-Prieto CA et al.
Bioinformatics (oxford, England), 2022
35512388 (PubMed )
Supplement: btac306_supplementary_data.zip › Supplementary_files.zip › Supplementary_files › Supplementary_file_9.xlsx › Sheet1
POLE/POLD1 mutation in non-exonuclease domain matters for predicting efficacy of immune-checkpoint-inhibitor therapy.
Chen YX et al.
Clinical and Translational Medicine, 2021
34586735 (PubMed )
Supplement: CTM2-11-e524-s001.xlsx › Supplementary_Table_6
Landscape of driver gene events, biomarkers, and druggable targets identified by whole-genome sequencing of glioblastomas.
van de Geer WS et al.
Neuro-oncology Advances, 0
35047820 (PubMed )
Supplement: vdab177_suppl_supplementary_data.xlsx › Figure5
Select a paper to view details